- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Trellis Bioscience Inc., a privately held biotechnology company, today announced the appointment of Bruce A. Keyt, Ph.D. as Chief Technology Officer and Vice President of Research. Dr. Keyt is a biotechnology industry veteran having more than 24 years scientific and management experience, including senior scientific and management positions at Abgenix, Millennium Pharmaceuticals, and Genentech. Most recently, Dr. Keyt was VP of Research and Development at Abmaxis prior to its acquisition by Merck, and acting VP of Preclinical Development at Ikaria, Inc.
"Bruce Keyt's long history within the biotechnology industry includes extensive background in many phases of drug development, including R&D work on six major projects that have resulted in marketed therapeutics," said Brian Cunningham, Chief Executive Officer of Trellis Bioscience. "His outstanding expertise in the preclinical development, protein chemistry and pharmacology of therapeutic antibody products will serve Trellis well as we advance our human antibody programs toward the clinic, in the areas of infectious disease and oncology."
As Vice President, Preclinical Development at Abgenix, Dr. Keyt led the efforts on the development of more than 20 therapeutics candidates in the field of cancer and inflammation, resulting in the filing of two INDs. Prior to that, he held senior management positions for four years at Millennium Pharmaceuticals, where, as director of biotherapeutics oncology, he led the group for validating targets and developing model systems for preclinical candidates. He began his professional career with a 16-year tenure at Genentech, where his efforts included work on six programs that have resulted in marketed drugs, including therapeutic antibodies Avastin, Lucentis and Vectabix. Dr. Keyt is the co-inventor in 12 granted US patents and author of over 50 scientific publications. He holds a Ph.D. degree in biochemistry and pharmacology from Tufts University School of Medicine.
About Trellis Bioscience
Trellis Bioscience, Inc. has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. The company’s proprietary CellSpot™ platform is at the convergence of nanotechnology, software, digital microscopy and biology and allows for a parallel evaluation of millions of cells simultaneously along more than 15 desired parameters in unprecedented detail. The technology has broad application in the discovery and production process development of therapeutic proteins. In addition to applying CellSpot™ to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology.
For more information, please click here
Trellis Bioscience, Inc.
Brian C. Cunningham, 650-616-1121
Joan Kureczka, 415-821-2413
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016
Doubling down on Schrödinger's cat May 27th, 2016
Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016